BCR-ABL kinase inhibitors: imatinib, dasatinib and nilotinib were developed to treat CML and imatinib now serves as the frontline therapy for the patients with chronic phase CML [16]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.